CARGO Therapeutics, Inc. (CRGX)
NASDAQ: CRGX · Real-Time Price · USD
4.125
-0.055 (-1.32%)
Mar 31, 2025, 10:47 AM EDT - Market open
Company Description
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022.
CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
CARGO Therapeutics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Nov 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 167 |
| CEO | Anup Radhakrishnan |
Contact Details
Address: 1900 Alameda De Las Pulgas, Suite 350 San Mateo, California 94403 United States | |
| Phone | 650 379 6143 |
| Website | cargo-tx.com |
Stock Details
| Ticker Symbol | CRGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001966494 |
| CUSIP Number | 14179K101 |
| ISIN Number | US14179K1016 |
| Employer ID | 84-4080422 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anup Radhakrishnan | Interim Chief Executive Officer, Chief Financial Officer, Secretary and Chief Operating Officer |
| Dr. Crystal L. Mackall M.D. | Co-Founder and Scientific Advisory Board Chair |
| Dr. Robbie Majzner M.D. | Co-Founder and Scientific Advisory Board Member |
| Nancy Goodman J.D. | Founder |
| Dr. Louai Labanieh | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | EFFECT | Notice of Effectiveness |
| Mar 21, 2025 | EFFECT | Notice of Effectiveness |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 12, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 12, 2025 | 10-K | Annual Report |
| Mar 12, 2025 | POSASR | Filing |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 21, 2025 | SCHEDULE 13D | Filing |